Since the expansion of the drug was approved, Medivation’s stock has increased about 60% and they raked ... Zytiga and Medivation’s (NASDAQ: MDVN) Xtandi. Xu gave Takai an Outperform rating and a $44 price target. Xu acknowledged …
On top of that, MDVN would get 40 percent of the profits. That's why the stock, which has more than doubled this year, is up big on the news (although it's already well off of its earlier highs). For Pfizer, of course, that's petty cash. For …
Now we own 400 shares, and the stock is way over $100 again ... relentlessly sucking billions from deep-pocket investors. Medivation (MDVN-$129), a biopharmaceutical company with 488 employees, is one of the exceptions that made it big.
MDVN is in an Uptrend called by SmarTrend on September 13, 2010 at $11.65. With a price of $22.81 at the end of April 2011, this stock has increased 93% since Smar-Trend’s Uptrend was issued. REGN (Regeneron Pharmaceuticals, …
The Biotech Investor has continued to show impressive growth in 2013. On Wednesday, the Nasdaq Biotechnology …
SmarTrend identified an Uptrend for Medivation (NASDAQ:MDVN) on July 7th, 2016 at $62.61. In approximately 11 months, Medivation has returned 30.06% as of today's recent price of $81.44. In the past 52 weeks, Medivation share prices …
And Medivation (MDVN) plunged 57% after its Alzheimer's drug failed a clinical ... But your aversion explains why Ferrovial SA (which trades actively on the Madrid stock exchange under the symbol FER.MC for about 8 euros and by …
Pharmaceutical firms Medivation (NASDAQ:MDVN) and Astellas Pharma (TYO:4503) said a co-developed drug prolonged overall survival in men with advanced prostate cancer by 4.8 months versus placebo. Medivation, based in San …
The quarter’s net profit at Rs.831 crore was about 7.3% lower than a year ago. Following the news on better sales numbers, the stock has inched up to outperform the benchmark indices. However, the next trigger would come as the …
Biotech has been the speculative driver in this market and many names exploded higher on Thursday. These include Receptos (RCPT), Medivation (MDVN), Bluebird (BLUE), and Incyte (INCY) to mention a few. IBB broke out of a short …